SOLBEC Pharmaceuticals has announced that its safety trial of Coamsine in the treatment of psoriasis has finished successfully and ahead of schedule.
This clinical trial, which was designed to demonstrate the safety of the compound under test, was conducted in three stages. The first two stages were concerned only with investigation of safety, tolerability and the time required for the drug to be absorbed, the duration of its activity, distribution in the body and excretion in healthy individuals.
The third stage recruited 10 psoriasis patients and looked additionally at efficacy for 56 days.
Solbec expects to receive the report into the effect of the third stage trial early in the second quarter of 2005.
